Mild or Moderate Covid-19

被引:941
|
作者
Gandhi, Rajesh T. [1 ,2 ]
Lynch, John B. [3 ]
del Rio, Carlos [4 ,5 ]
机构
[1] Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Univ Washington, Sch Med, Dept Med, Div Allergy & Infect Dis, Seattle, WA 98195 USA
[4] Emory Univ, Sch Med, Div Infect Dis, Dept Med, Atlanta, GA 30322 USA
[5] Grady Hlth Syst, Atlanta, GA USA
来源
NEW ENGLAND JOURNAL OF MEDICINE | 2020年 / 383卷 / 18期
关键词
DISEASE; 2019; COVID-19; CORONAVIRUS; CHLOROQUINE;
D O I
10.1056/NEJMcp2009249
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Mild or Moderate Covid-19 Covid-19 has a range of clinical manifestations, including cough, fever, myalgias, gastrointestinal symptoms, and anosmia. Diagnosis of Covid-19 is commonly made through detection of SARS-CoV-2 RNA by PCR testing of a nasopharyngeal swab or other specimens, including saliva. Antigen tests are generally less sensitive than PCR tests but are less expensive and can be used at the point of care with rapid results. Evaluation and management of Covid-19 depend on the severity of the disease. Patients with mild disease usually recover at home, whereas patients with moderate disease should be monitored closely and sometimes hospitalized. Remdesivir and dexamethasone have demonstrated benefits in hospitalized patients with severe Covid-19, but in patients with moderate disease, dexamethasone is not efficacious (and may be harmful) and data are insufficient to recommend for or against routine use of remdesivir. Infection control efforts center on personal protective equipment for health care workers, social distancing, and testing. The diagnosis of Covid-19 is usually based on SARS-CoV-2 PCR testing of a nasopharyngeal swab or other specimen. Remdesivir and dexamethasone have benefits in hospitalized patients with severe Covid-19, but in patients with moderate disease, dexamethasone is not efficacious and data are insufficient to recommend for or against routine use of remdesivir.
引用
收藏
页码:1757 / 1766
页数:10
相关论文
共 50 条
  • [1] Azithromycin for mild-to-moderate COVID-19
    Patel, Jigar
    Berezowski, Ivan
    Abdelmonem, Ahmed
    Taylor, Dania
    Pourmand, Ali
    [J]. LANCET RESPIRATORY MEDICINE, 2021, 9 (10): : E99 - E99
  • [2] Treatment of COVID-19 Patients with mild or moderate Disease
    Lichert, Frank
    [J]. PNEUMOLOGIE, 2021, 75 (03): : 174 - 174
  • [3] Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
    Dougan, M.
    Nirula, A.
    Azizad, M.
    Mocherla, B.
    Gottlieb, R. L.
    Chen, P.
    Hebert, C.
    Perry, R.
    Boscia, J.
    Heller, B.
    Morris, J.
    Crystal, C.
    Igbinadolor, A.
    Huhn, G.
    Cardona, J.
    Shawa, I
    Kumar, P.
    Adams, A. C.
    Van Naarden, J.
    Custer, K. L.
    Durante, M.
    Oakley, G.
    Schade, A. E.
    Holzer, T. R.
    Ebert, P. J.
    Higgs, R. E.
    Kallewaard, N. L.
    Sabo, J.
    Patel, D. R.
    Dabora, M. C.
    Klekotka, P.
    Shen, L.
    Skovronsky, D. M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (15): : 1382 - 1392
  • [4] Kidney outcome after mild to moderate COVID-19
    Schmidt-Lauber, Christian
    Haenzelmann, Sonja
    Schunk, Stefan
    Petersen, Elina L.
    Alabdo, Ammar
    Lindenmeyer, Maja
    Hausmann, Fabian
    Kuta, Piotr
    Renne, Thomas
    Twerenbold, Raphael
    Zeller, Tanja
    Blankenberg, Stefan
    Fliser, Danilo
    Huber, Tobias B.
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 (09) : 2031 - 2040
  • [5] Neutralizing Monoclonal Antibody for Mild to Moderate COVID-19
    Malani, Preeti N.
    Golub, Robert M.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 325 (07): : 644 - 645
  • [6] New Antiviral on the Horizon for Mild to Moderate COVID-19
    Harris, Emily
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 331 (10): : 821
  • [7] Neurological manifestations in mild and moderate cases of COVID-19
    Azim, Ghada Saed Abdel
    Osman, Marwa Abdellah
    [J]. EGYPTIAN JOURNAL OF NEUROLOGY PSYCHIATRY AND NEUROSURGERY, 2021, 57 (01):
  • [8] Neurological manifestations in mild and moderate cases of COVID-19
    Ghada Saed Abdel Azim
    Marwa Abdellah Osman
    [J]. The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 57
  • [9] Mild-to-Moderate COVID-19 Infection and Myocarditis: A Review
    Bailey, Eric
    Frishman, William H. H.
    [J]. CARDIOLOGY IN REVIEW, 2023, 31 (03) : 173 - 175
  • [10] The Impact of Isolation on Elderly Patients with Mild to Moderate COVID-19
    Sugiyama, Mizuki
    Kasai, Fumihito
    Kawate, Nobuyuki
    [J]. PROGRESS IN REHABILITATION MEDICINE, 2022, 7